CDC Warns of Rising US Rabies Exposures
Analysis based on 18 articles · First reported Sep 10, 2026 · Last updated Sep 11, 2026
The advisory is unlikely to move broad equity markets but could modestly lift demand expectations for rabies vaccine and immune globulin makers, a small niche of the pharmaceutical sector. Rising PEP utilization and CDC guidance on proper administration may draw regulatory and investor attention to vaccine supply and pricing without signaling any shortage.
The United States — Centers for Disease Control and Prevention issued a Health Alert Network advisory on Sept. 10, 2026, warning healthcare providers of a nationwide increase in human rabies exposures and errors in post-exposure prophylaxis (PEP) administration. Rabies-related inquiries rose 17% in July and August compared with the same period in 2025, and at least eight state health departments reported increased PEP use, administration errors, or both. Pharmacy data through Sept. 2 showed use of the two US-licensed rabies vaccines up 33% and human rabies immune globulin up 76% year over year. The alert followed several high-profile events, including a United States — North Carolina mobile petting zoo where baby goats tested positive for rabies and roughly 260 to 300 people were recommended shots, and a United States — Maryland state park where rabid beavers attacked people. The CDC said there is currently no shortage of rabies vaccine or immune globulin but stressed correct administration to avoid unnecessary treatment, adverse effects, and costs of up to $14,000 per course. The agency also noted rabies diagnostic testing, paused earlier in 2026 amid staff cuts, had resumed by early September. Health Secretary Robert F. Kennedy Jr. had previously downplayed rabies risks during a Senate hearing. The World Health Organization notes rabies is nearly 100% fatal once symptoms begin, making timely PEP critical.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard